Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year GrowthINGREZZA® (valbenazine) 2023 Net Pro...

Related Keywords

United States ,Neurocrine Bioscience ,Neurocrine Biosciences ,Kevin Gorman ,Diurnal Group ,Twitter ,Neurocrine Biosciences Inc ,Linkedin ,Nasdaq ,Facebook ,Prnewswire Neurocrine Biosciences Inc ,Third Quarter Net Product Sales ,Product Sales Guidance Raised ,Met Primary Endpoint ,Key Secondary Endpoints ,Congenital Adrenal ,Analyst Day ,New York City ,Chief Executive Officer ,December Analyst Day ,Months Ended September ,Per Share ,Cash Equivalents ,Marketable Securities ,Product Sales Highlights ,Quarter Financial Highlights ,New Drug Application ,Prescription Drug User Fee Act ,Operating Expense Guidance ,Product Sales ,Webcast Today ,Bioscience Analyst Day ,Quarterly Report ,